Comparison between urine and cervical samples for HPV DNA detection and typing in young women in Colombia by Cómbita, Aura Lucía et al.
Research Article
Comparison between Urine and Cervical
Samples for HPV DNA Detection and
Typing in Young Women in Colombia
Alba Lucía Combita1,2, Tarik Gheit3, Paula Gonzalez4, Devi Puerto5,
Raul Hernando Murillo5,6, Luisa Montoya7, Alex Vorsters8, Severien Van Keer8,
Pierre Van Damme8, Massimo Tommasino3, Gustavo Hernandez-Suarez5,
Laura Sanchez1, Rolando Herrero6, and Carolina Wiesner5
Abstract
Urine sampling for HPV DNA detection has been proposed
as an effective method for monitoring the impact of HPV
vaccination programs; however, conflicting results have been
reported. The goal of this study was to evaluate the performance
of optimized urine HPV DNA testing in women aged 19 to
25 years. Optimization process included the use of first void
urine, immediate mixing of urine with DNA preservative, and
the concentration of all HPV DNA, including cell-free DNA
fragments. Urine and cervical samples were collected from
535 young women attending cervical screening at health centers
from two Colombian cities. HPV DNA detection and genotyping
was performed using an HPV type-specific multiplex genotyping
assay, which combines multiplex polymerase chain reaction
with bead-based Luminex technology. Concordance between
HPV DNA detection in urine and cervical samples was deter-
mined using kappa statistics and McNemar tests. The accuracy of
HPV DNA testing in urine samples was evaluated measuring
sensitivity and specificity using as reference the results obtained
from cervical samples. Statistical analysis was performed using
STATA11.2 software. The findings revealed an overall HPV
prevalence of 60.00% in cervical samples and 64.72% in urine
samples, HPV-16 being the most frequent HPV type detected in
both specimens. Moreover, our results indicate that detection of
HPV DNA in first void urine provides similar results to those
obtained with cervical samples and can be used to monitor HPV
vaccination trials and programs as evidenced by the substantial
concordance found for the detection of the four vaccine types.
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Introduction
Three prophylactic HPV vaccines based on L1 virus like
particles (VLP) have been commercially developed: Cervarix,
a bivalent vaccine by GlaxoSmithKline against HPV-16 and -18
(1); Gardasil, a quadrivalent vaccine against HPV-6, -11, -16,
-18 (2); and Gardasil9, a nonavalent vaccine against HPV-6,
-11, -16, -18, -31, -33,- 45, -52, and 58; these two latter vaccines
by Merck (3). A large number of clinical trials have proven that
these vaccines are safe, well tolerated, highly immunogenic,
and effective in preventing persistent infections by HPV vaccine
types as well as cervical intraepithelial lesions associated with
them (4–18).
In Colombia, HPV vaccination was introduced in the Nation-
al Immunization Programme in 2012 as a primary prevention
strategy for HPV-16/-18-related preneoplastic and neoplastic
cervical lesions. The school-based program was initially
launched targeting a single-year age cohort (4th graders), but
since 2013 any girl between 14 and 17 years old was included.
In this context, the Colombian government is designing a
surveillance system, and the screening based on DNA testing
for HPV types could offer the opportunity to measure the
impact of a vaccination program in an early stage. Nevertheless,
an efficient and feasible method for detecting and genotyping
HPV with high analytical sensitivity is necessary (19, 20).
The use of a noninvasive and easy self-collection sampling
method, like a urine sample to detect HPV DNA, could offer a
more accessible and acceptable method to simplify HPV vac-
cine monitoring (19, 20). This approach could allow sampling
of large cohorts to measure the impact of HPV vaccination
programs in sentinel municipalities or within cohort studies
(20, 21). Several studies focused on cervical cancer screening
have reported a good performance to detect any HPV DNA in
urine samples with sensitivities ranging from 71 % to 88% and
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